Market Overview

Affymax May Run Out of Cash As Soon As 2Q, According to Analyst


Ian Somaiya, an analyst at Piper Jaffray, is suggesting that Affymax (NASDAQ: AFFY) may run out of cash sometime in mid-2012.

Somaiya reasons that Affymax has no timeline for potential re-introduction of Omontys and isn't able to estimate when it will complete the investigation surrounding the hypersensitivity issue that led to the recall.

Somaiya notes that Affymax may run out of cash because it only has $67 million in cash, with over $50 million in outstanding liabilities, (as of the end of February).

Some doctors have also suggested the drug may have "suffered permanent damage," and the road to recovery will be long.

AFFY is currently down ~7 percent in Tuesday's session, and was down ~12 percent near the lows of the day.

Latest Ratings for AFFY

Mar 2013DowngradesSell
Feb 2013DowngradesBuyNeutral
Feb 2013DowngradesMarket OutperformMarket Underperform

View More Analyst Ratings for AFFY
View the Latest Analyst Ratings

Posted-In: Analyst Color News FDA Analyst Ratings


Related Articles (AFFY)

View Comments and Join the Discussion!

Latest Ratings

TOLGoldman SachsInitiates Coverage On42.0
KBHGoldman SachsInitiates Coverage On36.0
YEXTSunTrust Robinson HumphreyMaintains28.0
LHCGSunTrust Robinson HumphreyMaintains160.0
DLRSunTrust Robinson HumphreyMaintains140.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

"Low Vol" ETF Inflows Underscore Rally's Risk-Off Nature

UPDATE: Eldorado Gold Issues Update on Vila Nova Mine, Says Temporarily Unable to Ship Ore from Site